Ann: CSL Vifor Market Briefing, page-14

Good article in the AFR.
https://www.copyright link/chanticleer/how-csl-s-boss-plans-to-turbocharge-vifor-after-19b-deal-20221017-p5bqhbSome excerpts from the article

"The underlying message was that Vifor finds itself in a similar position to CSL 10 years ago – it has a great suite of products and a strong R&D pipeline, but needs to focus on commercialisation."
Perreault points out that CSL’s last big acquisition, the flu vaccine business Seqirus in 2015, saw it buy a firm that was losing money. Vifor is profitable, but as a smaller biotech it has been more focused on short-term results, using a string of deals to keep driving growth.ut Perreault believes CSL’s scale – the business employs more than 32,000 people, with sales in more than 100 countries – can take growth to a new level.A key focus of Monday’s briefing was the looming IP cliff that Vifor faces as two of its key drugs lose exclusivity in 2023 and 2028.
Perreault understands the market’s concern, but is sanguine. Making iron injectables (a process that actually starts with the iron ore Australians know so well) is extremely complex, so generic competitors will likely take time to enter the market.

HT1